Limits...
HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma.

Movagharnejad K, Sharbatdaran M, Sheffaee S, Kashifard M, Sedaghat S - Int J Mol Cell Med (2013)

Bottom Line: Over-expression of HER-2/neu has been seen in several cancers such as gastric cancer and its expression is associated with poor prognosis.The over-expression of HER-2/neu has been observed in 6 patients (10%) and this over-expression was greater in the intestinal type of gastric adenocarcinoma than the diffuse type (12% vs. 6%); however, no statistically significant correlation between HER-2/neu expression and subtype, degree of differentiation, tumor type and age was observed.This over-expression was greater in differentiated types than undifferentiated types (18% vs. 5%).

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Rohani Hospital, Babol University of Medical Sciences, Babol, Iran.

ABSTRACT
Gastric adenocarcinoma is the second leading cause of death due to cancer in the world and in advanced stages the prognosis is poor even with current therapies. Over-expression of HER-2/neu has been seen in several cancers such as gastric cancer and its expression is associated with poor prognosis. The aim of this study is to evaluate the over-expression of HER-2/neu in gastric biopsy samples of patients with gastric carcinoma diagnosis; and to evaluate its probable relationship with clinical and pathological findings. The over-expression of HER-2/neu was examined retrospectively by immunohistochemistry method in 60 paraffin embedded samples collected in Babol, Iran, between 2010 and 2011. The over-expression of HER-2/neu has been observed in 6 patients (10%) and this over-expression was greater in the intestinal type of gastric adenocarcinoma than the diffuse type (12% vs. 6%); however, no statistically significant correlation between HER-2/neu expression and subtype, degree of differentiation, tumor type and age was observed. This over-expression was greater in differentiated types than undifferentiated types (18% vs. 5%).

No MeSH data available.


Related in: MedlinePlus

HER-2/neu overexpression score 2+.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3927378&req=5

Figure 3: HER-2/neu overexpression score 2+.


HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma.

Movagharnejad K, Sharbatdaran M, Sheffaee S, Kashifard M, Sedaghat S - Int J Mol Cell Med (2013)

HER-2/neu overexpression score 2+.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3927378&req=5

Figure 3: HER-2/neu overexpression score 2+.
Bottom Line: Over-expression of HER-2/neu has been seen in several cancers such as gastric cancer and its expression is associated with poor prognosis.The over-expression of HER-2/neu has been observed in 6 patients (10%) and this over-expression was greater in the intestinal type of gastric adenocarcinoma than the diffuse type (12% vs. 6%); however, no statistically significant correlation between HER-2/neu expression and subtype, degree of differentiation, tumor type and age was observed.This over-expression was greater in differentiated types than undifferentiated types (18% vs. 5%).

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Rohani Hospital, Babol University of Medical Sciences, Babol, Iran.

ABSTRACT
Gastric adenocarcinoma is the second leading cause of death due to cancer in the world and in advanced stages the prognosis is poor even with current therapies. Over-expression of HER-2/neu has been seen in several cancers such as gastric cancer and its expression is associated with poor prognosis. The aim of this study is to evaluate the over-expression of HER-2/neu in gastric biopsy samples of patients with gastric carcinoma diagnosis; and to evaluate its probable relationship with clinical and pathological findings. The over-expression of HER-2/neu was examined retrospectively by immunohistochemistry method in 60 paraffin embedded samples collected in Babol, Iran, between 2010 and 2011. The over-expression of HER-2/neu has been observed in 6 patients (10%) and this over-expression was greater in the intestinal type of gastric adenocarcinoma than the diffuse type (12% vs. 6%); however, no statistically significant correlation between HER-2/neu expression and subtype, degree of differentiation, tumor type and age was observed. This over-expression was greater in differentiated types than undifferentiated types (18% vs. 5%).

No MeSH data available.


Related in: MedlinePlus